ADC Therapeutics Q3 2026: ZYNLONTA Drives a Fourth Straight Beat

ADC Therapeutics posted an adjusted loss of $0.06 per share in Q3 2026, beating expectations for a $0.21 loss. Revenue of $21.72 million also came in ahead of estimates, driven primarily by higher ZYNLONTA unit volume.

Total operating expenses fell 24% year over year to $36.07 million, with R&D spending dropping as the company wound down discontinued programs. That combination of revenue growth and cost reduction shrank the operating loss meaningfully and marks the fourth consecutive quarter of clearing the consensus EPS bar.

In October 2026, the company completed a financial restructuring that management says pushes its cash runway into 2029. The moves included an $86.6 million private placement with investors including Bain Capital Life Sciences, Redmile, TCGX, and Nantahala Capital, alongside a paydown of its senior secured debt. Amortization requirements and a minimum liquidity covenant were also removed from the remaining loan.

The forward-looking picture is more complicated. The FDA raised serious concerns about the LOTIS-5 trial results at a pre-sBLA meeting, putting the regulatory path for a full ZYNLONTA approval in question. Full Phase 3 LOTIS-5 data are set to be presented at the American Society of Hematology meeting next month, making that event the most consequential near-term catalyst for the stock.

Also on the ASH agenda are updated Phase 1b results from LOTIS-7, which is testing ZYNLONTA in combination with glofitamab in relapsed or refractory large B-cell lymphoma, as well as investigator-initiated data in marginal zone lymphoma, mantle cell lymphoma, and Waldenström macroglobulinemia. Tanabe Pharma has also submitted a marketing authorization application in Japan for ZYNLONTA, adding a potential international approval milestone to the watch list heading into 2027.